Compare BBN & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BBN | ANL |
|---|---|---|
| Founded | 1983 | 2004 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Finance Companies | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.9M | 998.8M |
| IPO Year | 2010 | 2022 |
| Metric | BBN | ANL |
|---|---|---|
| Price | $14.40 | $15.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.50 |
| AVG Volume (30 Days) | ★ 254.7K | 139.1K |
| Earning Date | 01-01-0001 | 08-14-2026 |
| Dividend Yield | ★ 6.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $243.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.29 | $0.88 |
| 52 Week High | $17.45 | $17.25 |
| Indicator | BBN | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 24.49 | 59.60 |
| Support Level | N/A | $14.70 |
| Resistance Level | $16.02 | $17.10 |
| Average True Range (ATR) | 0.17 | 0.96 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 3.12 | 63.57 |
BlackRock Taxable Municipal Bond Trust is a diversified, closed-end management investment company. Its investment objective is to seek high current income, with a secondary objective of capital appreciation. The Trust seeks to achieve its investment objectives by investing in a portfolio of taxable municipal securities, including Build America Bonds (BABs), issued by state and local governments to finance capital projects such as public schools, roads, transportation infrastructure, bridges, ports and public buildings.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.